Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
Study on the Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies for Adult Myopia Treatment
1 other identifier
interventional
30
1 country
1
Brief Summary
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2025
CompletedStudy Start
First participant enrolled
September 20, 2025
CompletedFirst Posted
Study publicly available on registry
September 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2026
ExpectedSeptember 22, 2025
September 1, 2025
6 months
August 31, 2025
September 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Axial length
From enrollment to the end of treatment up to 7 months
Secondary Outcomes (2)
Spherical equivalent
From enrollment to the end of treatment up to 7 months
Choroidal thickness
From enrollment to the end of treatment up to 7 months
Study Arms (2)
The Laser Group
EXPERIMENTALUse Eyerising (RS-200-2A), 1 time,2 times or 3 times a day
The LED Group
EXPERIMENTALUse Airdoc (Sky-n1201), 2 times a day
Interventions
Eligibility Criteria
You may qualify if:
- years old, gender not limited; Obtained informed consent.
You may not qualify if:
- Obvious strabismus and amblyopia
- With congenital eye disease, such as congenital cataract, congenital retinal disease
- Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
- Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
- Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
- Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP\>21mmHg or binocular IOP difference ≥5mmHg)
- Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
- Optic nerve damage or congenital optic nerve dysfunction
- Can not be regularly checked
- The adjustment range is less than 8D or obvious near difficulties
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruihua Weilead
- Tianjin Medical University Eye Hospitalcollaborator
Study Sites (1)
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, 120120, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ruihua Wei
Tianjin Medical University Eye Hospital, Tianjin, Tianjin 120120 Recruiting
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 31, 2025
First Posted
September 22, 2025
Study Start
September 20, 2025
Primary Completion
March 20, 2026
Study Completion (Estimated)
June 20, 2026
Last Updated
September 22, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share